Vaxcyte Q2 net loss $166.6M, cash $2.83B; VAX-31 Phase 3 on track for Q4 start

Vaxcyte, Inc.

2025-Q2 EPS reported -$2.26

Net loss $166.6M for Q2 2025 vs $128.7M a year ago; R&D expenses $194.2M, up from $131.5M.
Cash, cash equivalents and investments $2.83B as of June 30, 2025; cash runway extended to mid-2028.
VAX-31 adult pivotal non-inferiority study to begin Q4 2025 with topline data expected in 2026.
VAX-31 infant Phase 2 modified: new optimized dose arm added, low dose arm discontinued; data by H1 2027.
Early pipeline streamlined: paused VAX-A1 and VAX-GI, discontinued VAX-PG due to insufficient efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.